Teva Just Cracked Open a Door Big Pharma Thought Was Locked

The appeals court didn't say Teva is right. It said the lower court needs to actually examine the question instead of brushing it aside. That's the door that just cracked open.

Why a "Narrow" Win Matters More Than You Think

Imagine you're a pharma company with a blockbuster drug facing Medicare negotiation. You know the negotiated price will be lower than what you currently charge. The IRA's penalty for refusing to play ball is brutal: an excise tax that can reach up to 95% of the drug's sales price. Your only other option is pulling out of Medicare and Medicaid entirely, which is business suicide for most drugs.

So your escape hatch is generic competition. Once a real generic enters the market, your drug comes off the negotiation list. But who decides what counts as "real" generic competition? That's exactly what the bona fide marketing standard governs.

If Teva can successfully challenge how CMS defines that threshold, it could change the timeline for when brand-name drugs exit the negotiation program. For companies watching their products inch toward the negotiation list, even a few months of delay or acceleration matters enormously. Revenue on these drugs can run into the hundreds of millions annually.

The Bigger Picture: A Legal Fortress With One Loose Brick

The pharmaceutical industry has been throwing legal spaghetti at the wall since 2023, when CMS kicked off the first round of negotiations for 10 high-spending Medicare Part D drugs. The arguments have ranged from First Amendment claims to excessive fines challenges under the Eighth Amendment. None have stuck.

The Second Circuit upheld the program against Boehringer Ingelheim. The Third Circuit did the same against AstraZeneca, and a separate Third Circuit panel rejected challenges from Bristol Myers Squibb and Janssen. Congressional Research Service reports confirm that no plaintiff's constitutional claim against the negotiation program has succeeded to date.

Meanwhile, the program keeps rolling. CMS announced the first set of negotiated prices in 2024, and those prices took effect in 2026. The savings are real: the first round alone is expected to cut roughly $1.5 billion in out-of-pocket costs for Medicare beneficiaries. CMS is set to begin formal rulemaking in 2026 for the program's fourth cycle, and by 2028, negotiations will expand to include Part B drugs (the ones administered in doctors' offices).

Against that backdrop, Teva's partial win looks small. But the pharmaceutical industry doesn't need a knockout punch right now. It needs precedent. It needs a court to say, "Hold on, let's look at this more carefully." That's exactly what happened.

What Pharma's Lawyers Are Thinking

The bona fide marketing question might sound like a technical footnote, but it's the kind of issue that shapes strategy across the industry. Several newer lawsuits are still working through the courts, including cases from AbbVie and the National Infusion Center Association. Those legal teams are now studying the D.C. Circuit's reasoning for clues about where CMS's implementation choices might be vulnerable, even if the program's overall structure remains intact.

The lesson from Teva's case is subtle but important: attacking the IRA's framework head-on doesn't work, but challenging specific CMS implementation decisions might. It's the difference between trying to tear down a building and looking for a window someone left unlocked.

Patient advocacy groups, for their part, described the ruling as a "major victory for patients" because the court upheld Medicare's core ability to negotiate lower prices for Austedo and Austedo XR. And that's fair. The program's foundation held firm.

The Bottom Line

Teva didn't win the war. It barely won a skirmish. But in a legal campaign where the pharmaceutical industry has been shut out at every turn, getting any issue remanded for further review counts as progress.

The IRA's drug pricing program isn't going anywhere. It's too popular with voters, too entrenched in CMS's operations, and too well-defended in court. But the details of how it works, the specific standards and timelines that determine which drugs get negotiated and for how long, are still being written. And now, thanks to a federal appeals court in D.C., at least one of those details is officially up for debate.

For an industry that's been losing in court for three straight years, that's not nothing.

BMS Just Hired a Robot to Design Its Next Blockbuster Antibody

Bristol Myers Squibb just partnered with a two-year-old AI startup to redesign how it discovers antibodies. Chai Discovery has already landed Eli Lilly, Novartis, and Pfizer as partners, and its AI models are posting hit rates that make traditional screening look ancient.